B oth men and women with psoriasis are equally at risk for developing psoriatic arthritis (PsA)-a chronic inflammatory ...

Icotrokinra was jointly discovered and is being developed pursuant to the license and collaboration agreement between ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

While Stelara is used in fewer indications than Humira, it commands a large market share in its therapeutic areas, most ...

The results of the Severe Psoriatic arthritis – Early intervEntion to control Disease ... suspect arthralgia and subclinical joint inflammation identified by MRI of the hands or feet. It included both ...

The primary outcome was mean Psoriatic Arthritis Disease Activity Score (PASDAS ... recommendations and clinical practice ...

Patients with psoriatic arthritis with a family history of psoriatic disease are diagnosed with psoriasis and psoriatic ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of its plaque psoriasis drug Sotyktu for the treatment of adults with active ...

Lyme disease is a complex condition with a long history of misdiagnosis, and Lyme arthritis, a late manifestation of the ...

If you qualify for both the enhanced daily living and enhanced mobility components of the payments, you will receive a total ...